Brief report · 30 Mar 2026
Case reportPublished 2019
Reduction of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Treated by Nivolumab
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nivolumab is an immune checkpoint inhibitor used to treat various advanced malignancies including metastatic non-small cell lung cancer. The side effects of immunotest inhibitors are different from traditional cytotoxic chemotherapy and pericardial effusion is one of the adverse effects of immunotherapy. However, here we present a 59-year-old male with advanced non-small cell lung cancer (NSCLC) treated with nivolumab who successfully managed reduction of pericardial effusion in patients treated by Nivolumab after 11 cycles. During the treatment, he underwent only one pericardial puncture and drainage of pericardial effusion.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Case Reports.
Opinion · 30 Mar 2026
Atypical Multiple Sclerosis in Young Adults: Challenges and Management
Brief report · 30 Mar 2026
Stress-Induced Heart Failure: The Mind-Heart Connection
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Case Reports
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Cai Z”
- BylineArticles whose byline prints “Tian X”
- BylineArticles whose byline prints “Dong L”
